P
Philip L. Lorenzi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 128
Citations - 22127
Philip L. Lorenzi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 37, co-authored 96 publications receiving 17665 citations. Previous affiliations of Philip L. Lorenzi include University of Michigan & Loyola University Chicago.
Papers
More filters
Journal ArticleDOI
Noncanonical role of singleminded-2s in mitochondrial respiratory chain formation in breast cancer
Steven Wall,L. Sánchez,Scott J. Pearson,Shiva Soma,Garhett L. Wyatt,Ramsey M. Jenschke,Lin Tan,Sara A. Martinez,Philip L. Lorenzi,Vishal M. Gohil,Monique Rijnkels,Weston Porter +11 more
TL;DR: In this article , the authors showed that the breast tumor suppressor gene SIM2 promotes mitochondrial oxidative phosphorylation (OXPHOS) using breast cancer cell line models and found that SIM2s functions not as a transcription factor but localizes to mitochondria and directly interacts with the MRC to facilitate functional supercomplex (SC) formation.
Journal ArticleDOI
Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer.
Susmita Ghosh,Fan Fan,Reid T. Powell,Jason Roszik,Yongsung Park,Clifford Stephan,Manu M. Sebastian,Lin Tan,Alexey V. Sorokin,Philip L. Lorenzi,Scott Kopetz,Lee M. Ellis,Rajat Bhattacharya +12 more
TL;DR: In this article , a combination of trametinib and vincristine was used to improve the efficacy of MEK inhibitors in patients with metastatic colorectal cancer (mCRC).
Posted ContentDOI
Suppression of membranous LRP5 recycling, WNT/β-catenin signaling, and colorectal tumorigenesis by 15-LOX-1 peroxidation of PI3P_linoleic acid
Fuyao Liu,Xiangsheng Zuo,Yi Liu,Yasunori Deguchi,Micheline J. Moussalli,Weidong Chen,Peiying Yang,Bo Wei,Philip L. Lorenzi,Shen Gao,Jonathan C. Jaoude,Amir Mehdizadeh,Lovie Ann Valentin,Daoyan Wei,Imad Shureiqi +14 more
TL;DR: These findings demonstrate for the first time that 15-LOX-1 metabolism of LA in PI3P to regulate LRP5 membrane abundance is a modifiable factor of Wnt/β-catenin aberrant signaling that could be potentially therapeutically targeted to suppress colorectal tumorigenesis and progression.